Safety of BTZ retreatment for patients with low-grade peripheral neuropathy during the initial treatment

Aleksandra P. Vidisheva, James Wang, Tanya M. Spektor, Jacob D. Bitran, Jose Lutzky, Imad A. Tabbara, Joseph Z. Ye, Sikander Ailawadhi, Laura V. Stampleman, Ronald G. Steis, Mehdi M. Moezi, Regina A. Swift, Tina M. Maluso, Kyle A. Udd, Shahrooz Eshaghian, Youram Nassir, James R. Berenson

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective: Neuropathy is an important complication that may limit treatment options for patients with multiple myeloma. Previous studies have focused on treatment efficacy and have shown that retreatment with bortezomib (BTZ) is an effective treatment option. The goal of this study was to focus on the clinical manifestations of peripheral neuropathy (PN) and to retrospectively compare the incidence and severity of PN between the initial BTZ regimen and upon retreatment. Furthermore, this study evaluated how certain factors affect BIPN, which will help determine what conditions should be considered prior to retreatment. Methods: Charts were reviewed from 93 patients who were retreated with a BTZ-containing regimen after previously being treated with this drug. Results: Among the patients who developed PN, most patients in the study had low-grade neuropathy during the initial BTZ treatment (n = 52, 68%). The results showed no evidence of cumulative toxicity, and there was no significant difference in the incidence and severity of PN upon retreatment. Factors such as the presence of baseline PN, number of prior treatments, dose of BTZ, and comorbidities did not increase the severity of PN upon retreatment. The lapse of time between the two regimens also did not affect the severity of PN. Conclusion: The results suggest that retreatment with BTZ may be a feasible option, without additional risks of PN, for MM patients even with peripheral neuropathy during their initial treatment with this drug.

Original languageEnglish (US)
Pages (from-to)1-8
Number of pages8
JournalSupportive Care in Cancer
DOIs
StateAccepted/In press - Apr 28 2017
Externally publishedYes

Fingerprint

Retreatment
Peripheral Nervous System Diseases
Safety
Therapeutics
Bortezomib
Incidence
Multiple Myeloma
Pharmaceutical Preparations
Comorbidity

Keywords

  • Bortezomib
  • Multiple myeloma
  • Peripheral neuropathy
  • Retreatment
  • Retrospective

ASJC Scopus subject areas

  • Oncology

Cite this

Vidisheva, A. P., Wang, J., Spektor, T. M., Bitran, J. D., Lutzky, J., Tabbara, I. A., ... Berenson, J. R. (Accepted/In press). Safety of BTZ retreatment for patients with low-grade peripheral neuropathy during the initial treatment. Supportive Care in Cancer, 1-8. https://doi.org/10.1007/s00520-017-3732-6

Safety of BTZ retreatment for patients with low-grade peripheral neuropathy during the initial treatment. / Vidisheva, Aleksandra P.; Wang, James; Spektor, Tanya M.; Bitran, Jacob D.; Lutzky, Jose; Tabbara, Imad A.; Ye, Joseph Z.; Ailawadhi, Sikander; Stampleman, Laura V.; Steis, Ronald G.; Moezi, Mehdi M.; Swift, Regina A.; Maluso, Tina M.; Udd, Kyle A.; Eshaghian, Shahrooz; Nassir, Youram; Berenson, James R.

In: Supportive Care in Cancer, 28.04.2017, p. 1-8.

Research output: Contribution to journalArticle

Vidisheva, AP, Wang, J, Spektor, TM, Bitran, JD, Lutzky, J, Tabbara, IA, Ye, JZ, Ailawadhi, S, Stampleman, LV, Steis, RG, Moezi, MM, Swift, RA, Maluso, TM, Udd, KA, Eshaghian, S, Nassir, Y & Berenson, JR 2017, 'Safety of BTZ retreatment for patients with low-grade peripheral neuropathy during the initial treatment', Supportive Care in Cancer, pp. 1-8. https://doi.org/10.1007/s00520-017-3732-6
Vidisheva, Aleksandra P. ; Wang, James ; Spektor, Tanya M. ; Bitran, Jacob D. ; Lutzky, Jose ; Tabbara, Imad A. ; Ye, Joseph Z. ; Ailawadhi, Sikander ; Stampleman, Laura V. ; Steis, Ronald G. ; Moezi, Mehdi M. ; Swift, Regina A. ; Maluso, Tina M. ; Udd, Kyle A. ; Eshaghian, Shahrooz ; Nassir, Youram ; Berenson, James R. / Safety of BTZ retreatment for patients with low-grade peripheral neuropathy during the initial treatment. In: Supportive Care in Cancer. 2017 ; pp. 1-8.
@article{9f13cb27e4ec4474af0922488003a1c3,
title = "Safety of BTZ retreatment for patients with low-grade peripheral neuropathy during the initial treatment",
abstract = "Objective: Neuropathy is an important complication that may limit treatment options for patients with multiple myeloma. Previous studies have focused on treatment efficacy and have shown that retreatment with bortezomib (BTZ) is an effective treatment option. The goal of this study was to focus on the clinical manifestations of peripheral neuropathy (PN) and to retrospectively compare the incidence and severity of PN between the initial BTZ regimen and upon retreatment. Furthermore, this study evaluated how certain factors affect BIPN, which will help determine what conditions should be considered prior to retreatment. Methods: Charts were reviewed from 93 patients who were retreated with a BTZ-containing regimen after previously being treated with this drug. Results: Among the patients who developed PN, most patients in the study had low-grade neuropathy during the initial BTZ treatment (n = 52, 68{\%}). The results showed no evidence of cumulative toxicity, and there was no significant difference in the incidence and severity of PN upon retreatment. Factors such as the presence of baseline PN, number of prior treatments, dose of BTZ, and comorbidities did not increase the severity of PN upon retreatment. The lapse of time between the two regimens also did not affect the severity of PN. Conclusion: The results suggest that retreatment with BTZ may be a feasible option, without additional risks of PN, for MM patients even with peripheral neuropathy during their initial treatment with this drug.",
keywords = "Bortezomib, Multiple myeloma, Peripheral neuropathy, Retreatment, Retrospective",
author = "Vidisheva, {Aleksandra P.} and James Wang and Spektor, {Tanya M.} and Bitran, {Jacob D.} and Jose Lutzky and Tabbara, {Imad A.} and Ye, {Joseph Z.} and Sikander Ailawadhi and Stampleman, {Laura V.} and Steis, {Ronald G.} and Moezi, {Mehdi M.} and Swift, {Regina A.} and Maluso, {Tina M.} and Udd, {Kyle A.} and Shahrooz Eshaghian and Youram Nassir and Berenson, {James R.}",
year = "2017",
month = "4",
day = "28",
doi = "10.1007/s00520-017-3732-6",
language = "English (US)",
pages = "1--8",
journal = "Supportive Care in Cancer",
issn = "0941-4355",
publisher = "Springer Verlag",

}

TY - JOUR

T1 - Safety of BTZ retreatment for patients with low-grade peripheral neuropathy during the initial treatment

AU - Vidisheva, Aleksandra P.

AU - Wang, James

AU - Spektor, Tanya M.

AU - Bitran, Jacob D.

AU - Lutzky, Jose

AU - Tabbara, Imad A.

AU - Ye, Joseph Z.

AU - Ailawadhi, Sikander

AU - Stampleman, Laura V.

AU - Steis, Ronald G.

AU - Moezi, Mehdi M.

AU - Swift, Regina A.

AU - Maluso, Tina M.

AU - Udd, Kyle A.

AU - Eshaghian, Shahrooz

AU - Nassir, Youram

AU - Berenson, James R.

PY - 2017/4/28

Y1 - 2017/4/28

N2 - Objective: Neuropathy is an important complication that may limit treatment options for patients with multiple myeloma. Previous studies have focused on treatment efficacy and have shown that retreatment with bortezomib (BTZ) is an effective treatment option. The goal of this study was to focus on the clinical manifestations of peripheral neuropathy (PN) and to retrospectively compare the incidence and severity of PN between the initial BTZ regimen and upon retreatment. Furthermore, this study evaluated how certain factors affect BIPN, which will help determine what conditions should be considered prior to retreatment. Methods: Charts were reviewed from 93 patients who were retreated with a BTZ-containing regimen after previously being treated with this drug. Results: Among the patients who developed PN, most patients in the study had low-grade neuropathy during the initial BTZ treatment (n = 52, 68%). The results showed no evidence of cumulative toxicity, and there was no significant difference in the incidence and severity of PN upon retreatment. Factors such as the presence of baseline PN, number of prior treatments, dose of BTZ, and comorbidities did not increase the severity of PN upon retreatment. The lapse of time between the two regimens also did not affect the severity of PN. Conclusion: The results suggest that retreatment with BTZ may be a feasible option, without additional risks of PN, for MM patients even with peripheral neuropathy during their initial treatment with this drug.

AB - Objective: Neuropathy is an important complication that may limit treatment options for patients with multiple myeloma. Previous studies have focused on treatment efficacy and have shown that retreatment with bortezomib (BTZ) is an effective treatment option. The goal of this study was to focus on the clinical manifestations of peripheral neuropathy (PN) and to retrospectively compare the incidence and severity of PN between the initial BTZ regimen and upon retreatment. Furthermore, this study evaluated how certain factors affect BIPN, which will help determine what conditions should be considered prior to retreatment. Methods: Charts were reviewed from 93 patients who were retreated with a BTZ-containing regimen after previously being treated with this drug. Results: Among the patients who developed PN, most patients in the study had low-grade neuropathy during the initial BTZ treatment (n = 52, 68%). The results showed no evidence of cumulative toxicity, and there was no significant difference in the incidence and severity of PN upon retreatment. Factors such as the presence of baseline PN, number of prior treatments, dose of BTZ, and comorbidities did not increase the severity of PN upon retreatment. The lapse of time between the two regimens also did not affect the severity of PN. Conclusion: The results suggest that retreatment with BTZ may be a feasible option, without additional risks of PN, for MM patients even with peripheral neuropathy during their initial treatment with this drug.

KW - Bortezomib

KW - Multiple myeloma

KW - Peripheral neuropathy

KW - Retreatment

KW - Retrospective

UR - http://www.scopus.com/inward/record.url?scp=85018263291&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018263291&partnerID=8YFLogxK

U2 - 10.1007/s00520-017-3732-6

DO - 10.1007/s00520-017-3732-6

M3 - Article

C2 - 28455546

AN - SCOPUS:85018263291

SP - 1

EP - 8

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

SN - 0941-4355

ER -